Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Rheumatology in Perspective · Olga Goodman, MD

Diagnosing Sjögren’s disease: from suspicion to a defensible conclusion

A clinical pathway for glandular, systemic and uncertain presentations.

Start with the clinical question, establish what each test actually measures, and document both supporting evidence and alternatives. Classification, diagnosis and treatment decisions overlap but answer different questions.

Evidence checked: 2026-09-22 · RheumaView original

Essentials

Sjögren’s disease (SjD) is a systemic autoimmune disease whose recognition often involves the eyes and salivary glands. The clinical entry point can also be pulmonary, neurological, haematological or renal. A diagnostic assessment should therefore have two parallel aims: determine whether SjD explains the presentation, and identify any organ problem that requires action before the diagnostic process is complete. [R01] [R15] [R16]

Three distinctions make the assessment more reliable. Subjective dryness is different from measured secretory impairment. Evidence of autoimmunity is different from proof that a particular symptom is caused by that autoimmunity. Finally, classification criteria standardise study populations; they are not a stand-alone rule for every individual diagnosis. These distinctions should be visible in the clinical record, rather than buried in a final label.

Working approach: establish the phenotype → look for competing explanations → obtain complementary objective evidence → assess organ involvement → state the level of confidence and the next decision. This is an editorial clinical framework, not a validated diagnostic prediction rule.

Clinical pathway: define the question before ordering the test

Ask what first raised suspicion. Was it persistent oral and ocular dryness, recurrent gland swelling, inflammatory arthritis, otherwise unexplained neuropathy, interstitial lung disease, a laboratory abnormality, or an incidental antibody result? These entry points do not carry the same prior probability. A positive test in an unselected person with nonspecific fatigue has a different meaning from the same result in someone with objectively documented gland dysfunction and characteristic systemic findings.

Build a timeline. Record symptoms before and after drying medications, a relevant infection, menopause, head-and-neck treatment or the onset of another autoimmune disease. Ask specifically about needing liquids with dry food, nocturnal oral dryness, dental deterioration, eye discomfort, gland swelling and the effect on work and sleep. Examination and history should also seek causes that can coexist with SjD. A competing contributor does not automatically negate autoimmune disease. [R17] [R18]

For each proposed investigation, finish the sentence: “If this result is positive or negative, I will…” A test that cannot influence the next decision may add ambiguity. Conversely, a clinically important question should not be abandoned because one convenient test is negative. Record what is still unknown so that the next specialist does not repeat the entire assessment.

Clinical pathway: use complementary evidence
EvidenceQuestion it helps answerWhat it cannot establish alone
Anti-SSA/Ro and the broader laboratory profileIs there serological evidence compatible with autoimmune disease?The cause of every symptom, disease activity or absence of SjD when negative
Ocular examination, staining and tear testingIs there ocular surface injury or impaired tear production, and what type of dry eye is present?Whether the cause is specifically SjD
Unstimulated salivary flowIs resting salivary output reduced under standardised conditions?The aetiology of that reduction
Minor salivary gland histologyIs there the relevant inflammatory pattern in an adequate sample?A complete diagnosis without clinical correlation
Major salivary gland ultrasoundIs gland architecture abnormal, or is there a focal lesion requiring a different pathway?Universal exclusion of SjD when normal

This table is a reasoning aid. Tests sample different biological compartments and can legitimately disagree. The task is to understand the disagreement, not to decide which single investigation always wins. [R02] [R03] [R04] [R19] [R20]

Full review: interpreting serology

Request and interpret the actual antibody result, assay and laboratory convention. A report headed “SSA” may not describe Ro52 and Ro60 in the same way across laboratories. A negative ANA does not necessarily mean that anti-SSA is absent; an ANA result should not automatically end a clinically justified SjD evaluation. Isolated anti-SSB without anti-SSA is not equivalent evidence to anti-SSA positivity. In the SICCA analysis, isolated SSB did not identify the characteristic phenotypic associations seen with SSA. [R05] [R06] [R21]

Other findings can inform the wider picture: blood counts, renal function, electrolytes, urinalysis, immunoglobulins and complement, with additional testing guided by the presentation. These investigations can expose an organ problem, an alternative diagnosis or a risk phenotype. They are not interchangeable diagnostic votes. A rheumatoid factor or raised IgG should not be treated as a substitute for the evidence required by the classification framework. [R21]

Explain the uncertainty in actionable terms. “SSA negative; objective gland testing pending” is more informative than either “no autoimmune disease” or a definitive SjD label based on symptoms alone. Repeating the same assay on a fixed schedule is not a substitute for resolving a particular clinical question.

Full review: eyes and salivary function

Ophthalmology contributes more than a Schirmer result. Surface staining, the tear film, eyelid disease, medication effects and other ocular pathology help distinguish overlapping mechanisms. Marked symptoms with modest test abnormalities deserve attention; they do not independently prove systemic immune activity. Conversely, relatively limited symptoms do not guarantee an intact ocular surface. The test result should include the method and conditions, rather than only “dry eye positive.” [R19] [R22]

For oral assessment, separate the sensation of dryness from measured flow and from its consequences. Document mucosal findings, dental disease, oral infection, gland enlargement and obstruction. Salivary flow depends on collection conditions. A standardised measurement is more interpretable than an unqualified report that “the mouth looked dry.” Consider drying medicines and hydration when planning testing; any medication adjustment must be coordinated with the prescriber. [R18] [R20] [R23]

The practical endpoint is not merely a diagnostic score. A patient with low salivary output or significant ocular surface disease needs protection of teeth or eyes while the aetiological assessment proceeds. Diagnostic uncertainty should be documented without becoming a reason to withhold appropriate local care.

Decision thresholds: use the numbers without mistaking them for a diagnosis

In the 2016 framework, anti-SSA and qualifying labial histology each contribute three points; each qualifying ocular or salivary functional item contributes one. Classification requires at least four points in an eligible person without an exclusion. The relevant thresholds are focus score ≥1 per 4 mm², ocular staining score ≥5 or van Bijsterveld ≥4 in at least one eye, Schirmer ≤5 mm/5 minutes in at least one eye, and unstimulated whole saliva ≤0.1 mL/min. Refer to the original paper for the complete instrument and conditions. [R02]

Two important consequences: an SSA-negative person needs qualifying histology and at least one qualifying functional item to meet this framework; objective abnormalities in both the eyes and mouth are not required. Conversely, three functional points without either SSA or qualifying histology cannot reach the threshold. Those are properties of this classification system, not instructions to deny symptom care or discontinue the differential diagnosis.

A boundary value is not a biological cliff. French and Korean studies examined how age and sex influence the interpretation of salivary measurements; recent Chinese work is also investigating age-specific references. These studies raise a legitimate calibration question, but do not by themselves replace the published classification threshold. Record the actual value, sampling conditions and uncertainty rather than silently substituting an alternative cut-off. [R54] [R55] [R56]

Full review: classification without overreach

The 2016 ACR/EULAR criteria combine anti-SSA, qualifying labial histology and objective ocular/oral measurements in an eligible population. Anti-SSA and qualifying histology carry the greatest weight. For an SSA-negative person, positive qualifying histology is necessary to reach the classification threshold; histology by itself is insufficient. The original instrument contains eligibility conditions, exclusions and methodological details that should be consulted directly. This page does not reproduce the scoring instrument or supply an automated diagnostic calculator. [R02]

Relevant exclusions in that classification framework include prior head-and-neck radiation, active hepatitis C confirmed by PCR, AIDS, sarcoidosis, amyloidosis, graft-versus-host disease and IgG4-related disease. Avoid silently broadening a criterion: for example, the original wording is not a generic exclusion of every person with HIV. Classification exclusions also do not replace a patient-specific differential diagnosis. [R02]

A useful conclusion records both clinical judgement and classification status: “Clinical assessment supports SjD; ACR/EULAR classification met/not met/not assessable.” If evidence remains incomplete, state that explicitly. Failure to meet criteria can reflect absent evidence, unavailable testing or a genuinely different condition; those are different problems with different next steps.

The differential: distinguish mimics, contributors and overlaps
Clinical patternCompeting or coexisting explanationDiscriminating approach
Dryness after a treatment changeAnticholinergic or other drying drugs; checkpoint-inhibitor-associated siccaTemporal relationship, medication review, objective gland assessment; checkpoint-associated disease may differ from conventional SjD
Eye discomfort with relatively preserved tear productionEvaporative dry eye, lid disease, sensory dysfunction or another ocular disorderExamine the tear film, surface and lids; relate signs to symptoms
Dry mouth or oral burningReduced secretion, candidiasis, mucosal disease or a pain disorderMeasure function when relevant; inspect the mouth rather than equating burning with dryness
Large or focally abnormal salivary glandsObstruction, infection, IgG4-related disease, granulomatous or lymphoproliferative diseaseCharacterise the distribution and lesion; choose sampling that addresses the actual differential
Another established autoimmune diseaseAssociated SjD, medication effects or unrelated siccaNeither the overlap diagnosis nor the dryness alone establishes glandular autoimmunity

The table is an original clinical synthesis of the diagnostic questions; the listed alternatives do not all have equal probability in every presentation. An explanation may account for one symptom while leaving another unexplained. A patient can have SjD and meibomian gland dysfunction, or SjD and drug-related worsening of oral dryness. [R18] [R36] [R62] [R72]

Complex questions: systemic disease and competing explanations

Do not require dramatic sicca before considering SjD in a compatible systemic presentation. Equally, do not attribute an organ disorder to SjD simply because an antibody or lip biopsy is positive. For neuropathy, establish the neurological phenotype and evaluate relevant alternative causes. For cough or dyspnoea, distinguish airway, parenchymal and non-pulmonary explanations through the appropriate pulmonary assessment. Specialty guidance supports organ-specific evaluation rather than a single universal investigation bundle. [R15] [R16] [R24]

A persistent focal salivary lesion or progressive asymmetric enlargement poses a different question from diffuse sicca. A routine lip biopsy may not sample the lesion responsible. Infection, obstruction and lymphoproliferative disease require targeted consideration; the sampling site and technique should follow the lesion and specialist assessment. [R25]

Separate diagnostic confidence from urgency. Significant visual symptoms, rapidly evolving neurological deficit or severe respiratory symptoms cannot safely wait for a completed SjD work-up. An urgent organ assessment may proceed while the autoimmune attribution remains unresolved. This is a clinical priority decision, not evidence that every such symptom is caused by SjD.

Complex questions: time, geography and uncertainty

Sjögren’s evidence comes from differently selected populations. The international criteria collaboration, the US-based SICCA infrastructure, European referral cohorts and Chinese hospital cohorts answer related but non-identical questions. Compare entry criteria, antibody methods, biopsy requirements and referral patterns before comparing percentages. A high proportion of lung disease in a pulmonary or tertiary referral population is not the expected risk for every patient attending a general sicca clinic. [R07] [R08] [R09]

Some patients remain in an interval of uncertainty. Longitudinal SICCA observations show that many measured features are stable over a few years, while a subset changes classification status. They do not justify promising eventual seroconversion or repeating invasive tests by the calendar. Reassessment should be tied to a meaningful change, a previously inadequate investigation or a decision that new evidence can resolve. [R10]

Access is part of interpretation. If expert ocular staining, ultrasound or pathology is unavailable, record the limitation. Do not convert “not performed” into “normal.” A referral, pathology review or carefully documented follow-up may be more informative than a large unselected test panel.

Baseline assessment: look beyond a sicca score

Document a baseline that can later distinguish a new manifestation from pre-existing disease. A focused review should cover gland and lymph-node enlargement, skin lesions, inflammatory joint features, respiratory symptoms and exercise tolerance, neurological symptoms and renal clues. Laboratory selection commonly includes blood counts, kidney function, electrolytes including bicarbonate, urinalysis and, when indicated, urine protein quantification, immunoglobulins and complement. Add tests because of the question they answer: for example, cryoglobulin testing with appropriate sample handling for a compatible vasculitic phenotype, or monoclonal-protein assessment for a relevant haematological concern. [R21] [R47]

Neurological pitfall: routine nerve-conduction studies assess large fibres and can be normal in small-fibre neuropathy. Symptoms alone still do not prove its presence or SjD attribution; the phenotype determines whether skin biopsy, appropriate small-fibre testing or autonomic assessment is informative. [R57] Renal pitfall: filtration and tubular acid/electrolyte handling are different functions. A reassuring creatinine should not end evaluation of otherwise unexplained hypokalaemia, acidosis or recurrent stones. [R66] [R71]

Pulmonary symptoms warrant a targeted pathway; clinical guidance discusses pulmonary function testing and imaging according to presentation. Do not convert a comprehensive baseline history into automatic serial CT, PET or invasive testing for every patient. Equally, do not treat a low overall activity score as a reason to ignore an important individual organ abnormality. [R16]

Children, men and international applicability

Adult sicca-centred expectations can underperform in childhood disease. In an international cohort of 300 children, recurrent parotitis was an important presentation and application of adult criteria was limited by both phenotype and incomplete testing. Failure to fulfil adult criteria in a child is therefore not equivalent to exclusion; evaluation belongs in a paediatric specialist context. [R61]

Female predominance should influence epidemiological expectations without becoming a diagnostic requirement. A male patient needs the same disciplined assessment of objective findings and alternatives. The clinically useful question is how the phenotype and referral setting affect probability, rather than whether the patient matches a stereotype.

International evidence map: ACR/EULAR supplies a shared classification framework; the UK BSR guideline integrates adult and juvenile assessment; US specialty guidance adds organ-specific detail; Korean and Chinese diagnostic cohorts examine measurement and phenotype differences. JCR lists a 2025 Japanese guideline edition. Its existence is verified here, but detailed Japanese recommendations are not inferred from a publication notice. Local test availability and validated laboratory methods still matter. [R47] [R15] [R55] [R64]

A practical consultation record
  1. Presenting question: what pattern raises suspicion, and what is the patient most concerned about?
  2. Objective evidence: actual values and reports, methods, dates, sample adequacy and relevant confounders.
  3. Alternative and coexisting causes: which have been evaluated, and which remain open?
  4. Organ assessment: findings requiring treatment, referral or accelerated investigation.
  5. Conclusion: confidence in SjD, classification status and attribution of individual manifestations.
  6. Next decision: the purpose of any additional test, follow-up trigger and who is responsible.

This proposed documentation structure is an original practice aid. It is not a validated instrument. Its purpose is to make the reasoning reviewable across rheumatology, ophthalmology, oral medicine and other specialties, while giving the patient a clear explanation of what is established and what remains uncertain.

Evidence and next reading

The most useful next chapter is Anti-SSA-negative disease and discordant tests. For patient communication, use Understanding Sjögren’s: diagnosis and first steps. Key sources include the original ACR/EULAR criteria, histopathology standardisation, the SICCA isolated-SSB and longitudinal analyses, and primary Chinese seronegative cohorts. Source links appear with the relevant statements and in the reference list.

Evidence boundary: this chapter is an evidence-informed clinical synthesis, not a prospectively validated pathway. It focuses on diagnosis; treatment selection, comprehensive organ algorithms and drug pipelines require their own chapters. Regional cohorts are compared where they inform this diagnostic question, without implying that they represent every healthcare system.

Sources

  1. R01 Rome consensus on Sjögren disease nomenclature (2025)
    International consensus
  2. R02 2016 ACR/EULAR classification criteria for primary Sjögren’s syndrome
    Original classification study
  3. R03 Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren’s syndrome (2017)
    International methods consensus
  4. R04 Normal salivary gland ultrasonography in anti-SSA-negative patients with sicca (2021)
    France; primary diagnostic cohort
  5. R05 The SSB-positive/SSA-negative antibody profile in SICCA (2015)
    International cohort; primary analysis
  6. R06 Current state of technologies and recognition of anti-SSA/Ro antibodies in China (2021)
    China; multicentre laboratory study
  7. R07 Seronegative primary Sjögren’s syndrome, a distinct subtype (2024)
    China; retrospective cohort
  8. R08 Antibody-negative phenotype in a Chinese cohort of 934 patients
    China; retrospective single-centre cohort
  9. R09 SICCA international collaboration and criteria development
    Same primary study as R02; alternate access
  10. R10 Natural history and predictors of progression in the SICCA registry (2018)
    International longitudinal cohort
  11. R15 Peripheral nervous system clinical practice guideline for Sjögren’s disease (2025/2026)
    US; specialty guideline
  12. R16 Consensus guidelines for pulmonary disease in Sjögren’s (2021)
    US; specialty guideline
  13. R17 Diagnosis of Sjögren’s disease
    Johns Hopkins; clinical education
  14. R18 Dry mouth
    US NIH/NIDCR; patient education
  15. R19 Schirmer’s test
    Johns Hopkins; test explanation
  16. R20 Sialometry
    Johns Hopkins; test explanation
  17. R21 Blood and urine tests
    Johns Hopkins; clinical education
  18. R22 Management of dry eye
    Johns Hopkins; clinical education
  19. R23 Preventing dental decay
    Johns Hopkins; clinical education
  20. R24 Neurologic complications
    Johns Hopkins; clinical education
  21. R25 Parotid swelling and prediction of lymphoma in Sjögren’s syndrome (2023)
    Europe; primary observational study
  22. R36 Burning mouth syndrome
    US NIH/NIDCR; patient education
  23. R47 BSR guideline on adult and juvenile onset Sjögren disease (online 2024; issue 2025)
    UK; multidisciplinary guideline
  24. R54 Unstimulated saliva: reassessing the diagnostic threshold (2020)
    France; primary diagnostic study
  25. R55 Age, salivary flow and gland ultrasound in Sjögren diagnosis (2022)
    South Korea; primary diagnostic study
  26. R56 Age-specific salivary flow reference values (2026)
    China; cross-sectional diagnostic research
  27. R57 Sjögren-associated small-fibre neuropathy: prospective series of 40 cases (2013)
    France; primary neurological cohort
  28. R61 Childhood Sjögren: international cohort of 300 children (2021)
    International primary paediatric cohort
  29. R62 TFOS DEWS III: diagnostic methodology (2025)
    International ophthalmology consensus
  30. R64 Japan College of Rheumatology: Sjögren guideline, 2025 edition
    Official publication notice; detailed recommendations not reproduced here
  31. R66 Renal involvement in primary Sjögren: prospective cohort (2018)
    India; primary prospective cohort
  32. R71 Distal renal tubular acidosis in primary Sjögren (2015)
    Netherlands; primary cohort
  33. R72 Sicca/Sjögren-like disease after immune checkpoint inhibitors (2019)
    International primary case series

↑ All articles

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Diagnostic evidenceSjögren diseaseSymptoms and diagnosis